Ascentage Pharma Group International
ASPHFOTCHealthcare● Active
$4.53
$-0.17(-3.51%)
Market Cap$1.7B
P/E Ratio—
52W High$10.65
52W Low$4.53
Ascentage Pharma Group International (ASPHF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ASPHF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.56B | $0.98B | $0.22B | $0.21B | $0.03B |
| Cost of Revenue | $0.13B | $0.03B | $0.03B | $0.02B | $0.00B |
| Gross Profit | $0.43B | $0.95B | $0.19B | $0.19B | $0.02B |
| Gross Margin %(computed) | 76.41% | 97.03% | 86.24% | 89.51% | 88.08% |
| Operating Expenses | |||||
| R&D Expenses | $1.08B | $0.95B | $0.71B | $0.74B | $0.77B |
| G&A Expenses | $0.00B | $0.19B | $0.18B | $0.17B | $0.14B |
| Total Operating Expenses | $1.61B | $1.32B | $1.06B | $1.03B | $0.85B |
| Operating Income | ($1.18B) | ($0.37B) | ($0.87B) | ($0.88B) | ($0.93B) |
| Operating Margin %(computed) | -211.14% | -37.70% | -393.11% | -421.25% | — |
| Interest Income | $0.08B | $0.04B | $0.03B | $0.01B | $0.01B |
| Interest Expense | $0.05B | $0.06B | $0.10B | $0.05B | $0.02B |
| Income Before Tax | ($1.20B) | ($0.40B) | ($0.93B) | ($0.89B) | ($0.83B) |
| Income Tax Expense | $0.01B | $0.01B | ($0.01B) | ($0.00B) | ($0.05B) |
| Net Income | ($1.21B) | ($0.41B) | ($0.93B) | ($0.88B) | ($0.78B) |
| Net Margin %(computed) | -216.47% | -41.34% | -416.98% | -421.02% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.43 | $-1.37 | $-3.28 | $-3.35 | $-3.07 |
| Wtd Avg Shares | 0.36B | 0.30B | 0.28B | 0.26B | 0.25B |
| EBITDA | ($1.10B) | ($0.24B) | ($0.74B) | ($0.84B) | ($0.92B) |
| EBITDA Margin %(computed) | -196.08% | -24.23% | -334.98% | -398.64% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CNY · B
Explore more Ascentage Pharma Group International data
About Ascentage Pharma Group International (ASPHF) Income Statement
Ascentage Pharma Group International (ASPHF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ASPHF reported revenue of $0.56B, gross profit of $0.43B (gross margin 76.41%), and net income of ($1.21B) — a net profit margin of -216.47%.
Frequently asked questions
ASPHF · 4 questionsAscentage Pharma Group International (ASPHF) reported revenue of $0.56B for 2025, down 43.0% year-over-year.
ASPHF revenueASPHF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08